Assessment of the systemic distribution of a bioconjugated anti-Her2 magnetic nanoparticle in a breast cancer model by means of magnetic resonance imaging

被引:0
|
作者
L. F. E. Huerta-Núñez
G. Cleva Villanueva-Lopez
A. Morales-Guadarrama
S. Soto
J. López
J. G. Silva
N. Perez-Vielma
E. Sacristán
Marco E. Gudiño-Zayas
C. A. González
机构
[1] Universidad del Ejercito y FAM/EMGS-Laboratorio Multidisciplinario de Investigación,Departamento de Medicina Experimental, Facultad de Medicina
[2] Instituto Politécnico Nacional-Escuela Superior de Medicina-Sección Investigación y Posgrado,undefined
[3] Centro Nacional de Investigacion en Imagenologia e Instrumentacion Medica-Universidad Autónoma,undefined
[4] Instituto Politécnico Nacional - Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás (CICS-UST),undefined
[5] UNAM,undefined
来源
关键词
Breast cancer; Magnetic nanoparticles; Anti-Her2; Systemic distribution; Magnetic resonance imaging; Nanomedicine;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this study was to determine the systemic distribution of magnetic nanoparticles of 100 nm diameter (MNPs) coupled to a specific monoclonal antibody anti-Her2 in an experimental breast cancer (BC) model. The study was performed in two groups of Sprague–Dawley rats: control (n = 6) and BC chemically induced (n = 3). Bioconjugated “anti-Her2-MNPs” were intravenously administered, and magnetic resonance imaging (MRI) monitored its systemic distribution at seven times after administration. Non-heme iron presence associated with the location of the bioconjugated anti-Her2-MNPs in splenic, hepatic, cardiac and tumor tissues was detected by Perl’s Prussian blue (PPB) stain. Optical density measurements were used to semiquantitatively determine the iron presence in tissues on the basis of a grayscale values integration of T1 and T2 MRI sequence images. The results indicated a delayed systemic distribution of MNPs in cancer compared to healthy conditions with a maximum concentration of MNPs in cancer tissue at 24 h post-infusion.
引用
收藏
相关论文
共 50 条
  • [31] The utility of preoperative breast magnetic resonance imaging in invasive breast cancer according to HER2 status.
    McLaughlin, S. A.
    Vallow, L. A.
    Hines, S. L.
    Tan, W.
    CANCER RESEARCH, 2009, 69 (02) : 257S - 257S
  • [32] Magnetic-resonance imaging for breast cancer
    Drew, PJ
    Turnbull, LW
    Kerin, MJ
    LANCET, 1998, 351 (9116): : 1661 - 1662
  • [33] Magnetic Resonance Perfusion Imaging for Breast Cancer
    Udayakumar, Durga
    Madhuranthakam, Ananth J.
    Dogan, Basak E.
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2024, 32 (01) : 135 - 150
  • [34] Magnetic resonance imaging of invasive breast cancer
    Corr, P.
    Panday, S.
    Seolall, P.
    Booth, H.
    SA JOURNAL OF RADIOLOGY, 2005, 9 (03): : 4 - 6
  • [35] Magnetic Resonance Imaging in Breast Cancer Recurrence
    P. Belli
    M. Costantini
    M. Romani
    P. Marano
    G. Pastore
    Breast Cancer Research and Treatment, 2002, 73 : 223 - 235
  • [36] Magnetic resonance imaging in breast cancer recurrence
    Belli, P
    Costantini, M
    Romani, M
    Marano, P
    Pastore, G
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 73 (03) : 223 - 235
  • [37] Imaging in breast cancer: Magnetic resonance spectroscopy
    Patrick J Bolan
    Michael T Nelson
    Douglas Yee
    Michael Garwood
    Breast Cancer Research, 7
  • [38] Magnetic-resonance imaging in breast cancer
    Boggis, CRM
    Bundred, NJ
    LANCET, 1998, 351 (9112): : 1362 - 1362
  • [39] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Stanowicka-Grada, Malwina
    Senkus, Elzbieta
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
  • [40] Magnetic Resonance Imaging in Screening of Breast Cancer
    Gao, Yiming
    Reig, Beatriu
    Heacock, Laura
    Bennett, Debbie L.
    Heller, Samantha L.
    Moy, Linda
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2021, 59 (01) : 85 - 98